Earnings ·
Nuvation Bio reports Q3 revenue of $45.0M and net loss of $(0.12) per share
NUVBNuvation Bio Inc.
Nuvation Bio Inc. reported third-quarter 2026 total revenue of $45.0 million, driven by $27.5 million in net product sales for IBTROZI (taletrectinib) and $17.5 million from collaboration and license agreements. The company posted a net loss of $41.9 million, or $(0.12) per share, compared to a net loss of $55.8 million, or $(0.16) per share, in the prior-year period. Cash, cash equivalents, and marketable securities stood at $663.4 million as of September 30, 2026. The filing also highlighted FDA approval of a supplemental label for IBTROZI reflecting a median duration of response of 49.7 months and Fast Track Designation for safusidenib in IDH1-mutant glioma. Nuvation Bio is a global oncology company focused on developing therapies for cancer treatment.